May 21 (Reuters) - Moderna (MRNA.O), opens new tab said on Wednesday it has withdrawn an application seeking approval for its flu and COVID combination vaccine candidate to wait for efficacy data from ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Moderna's decision to withdraw ...
KLAS Las Vegas on MSN
Federal indictment alleges scheme involving 12 defendants took more than $14 million in COVID loans
A Las Vegas-based tax preparer and 11 others described as co-conspirators were indicted Tuesday by a federal grand jury in connection with a COVID-19 relief loan application scheme worth more than $14 ...
Manufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as early as August, pending regulatory approval The most common solicited local adverse event for ...
CLAIM: A COVID-19 test patent application is dated 2020 but was actually filed in 2015. THE FACTS: The patent application, for a system to determine if someone has a viral infection such as COVID-19, ...
Novavax said the Food and Drug Administration has put a hold on its application for a combination shot targeting Covid and influenza and a stand-alone flu vaccine, sending shares of the company down ...
Moderna Inc. said it has “voluntarily” withdrawn its application for regulatory approval for its combination Covid and flu shot for people 50 and over, a setback for the company. The biotech company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results